Well, again, we know now from the projects we've already funded that they can produce the technetium-99, which is the substance that goes into a patient's body. We know they can produce it and they can replicate that process.
The question now is about ensuring that you would have the right kind of purity of the product on a consistent basis, and that you would meet the regulatory requirements, and also about trying to develop some kind of standardization of the process so that you can do it on a commercial level or a commercial scale. That's what we still need to do with this additional funding support to get it there. Clearly, we would like to have, by 2016, a reasonable dissemination of those technologies in Canada, to start meeting the needs of Canadians when the NRU basically comes to an end as regards the production of medical isotopes.